Skip to content

Puma gets nod from FDA panel on breast cancer med

May 24, 2017

Puma Biotechnology Inc. shares PBYI, +28.93% surged 20% in afternoon trade Wednesday, after the company said an advisory committee for the U.S. Food and Drug Administration has voted 12 to 4 in favor of recommending approval for the company’s neratinib treatment for breast cancer. The vote came after a review of the clinical development program for the drug, which aims to prevent recurrence in early-stage breast cancer patients. Puma stock already rallied Tuesday, after the FDA released favorable briefing documents for the advisory committee meeting. The stock has gained 135% in 2017 so far, while the S&P 500 SPX, +0.25% has gained 7%.

http://on.mktw.net/2qkYWrz

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: